Thermo Fisher Scientific Financial Statements (TMO)
|
|
|
|
Report date
|
|
|
25.02.2021 |
24.02.2022 |
31.12.2022 |
23.02.2023 |
22.02.2024 |
|
01.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
32 218 |
39 211 |
44 915 |
44 915 |
42 857 |
|
42 278 |
|
Operating Income, bln rub |
|
|
7 794 |
10 028 |
8 393 |
8 393 |
6 859 |
|
7 330 |
|
EBITDA, bln rub |
? |
|
10 192 |
12 964 |
11 760 |
11 941 |
10 800 |
|
10 406 |
|
Net profit, bln rub |
? |
|
6 375 |
7 725 |
6 950 |
6 950 |
5 995 |
|
6 367 |
|
|
OCF, bln rub |
? |
|
8 289 |
9 543 |
9 154 |
9 154 |
8 406 |
|
8 252 |
|
CAPEX, bln rub |
? |
|
1 474 |
2 523 |
2 243 |
2 243 |
1 479 |
|
1 522 |
|
FCF, bln rub |
? |
|
6 815 |
7 020 |
6 911 |
6 911 |
6 927 |
|
8 026 |
|
Dividend payout, bln rub
|
|
|
337.0 |
395.0 |
455.0 |
455.0 |
523.0 |
|
598.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
5.29% |
5.11% |
6.55% |
6.55% |
8.72% |
|
9.39% |
|
|
OPEX, bln rub |
|
|
8 612 |
10 009 |
8 598 |
10 993 |
22 830 |
|
12 780 |
|
Cost of production, bln rub |
|
|
15 713 |
18 977 |
25 415 |
25 415 |
27 633 |
|
25 176 |
|
R&D, bln rub |
|
|
1 181 |
1 406 |
1 471 |
1 471 |
1 337 |
|
1 370 |
|
Interest expenses, bln rub |
|
|
553.0 |
536.0 |
726.0 |
726.0 |
1 375 |
|
1 420 |
|
|
Assets, bln rub |
|
|
69 052 |
95 123 |
97 290 |
97 154 |
98 726 |
|
100 364 |
|
Net Assets, bln rub |
? |
|
34 507 |
40 793 |
44 032 |
43 978 |
46 735 |
|
48 992 |
|
Debt, bln rub |
|
|
21 735 |
34 870 |
34 488 |
34 488 |
34 917 |
|
35 313 |
|
Cash, bln rub |
|
|
10 325 |
4 477 |
8 524 |
8 524 |
8 077 |
|
6 645 |
|
Net debt, bln rub |
|
|
11 410 |
30 393 |
25 964 |
25 964 |
26 840 |
|
28 668 |
|
|
Ordinary share price, rub |
|
|
465.8 |
667.2 |
550.7 |
550.7 |
530.8 |
|
447.5 |
|
Number of ordinary shares, mln |
|
|
396.0 |
394.0 |
392.0 |
392.0 |
386.0 |
|
382.0 |
|
|
Market cap, bln rub |
|
|
184 449 |
262 893 |
215 870 |
215 870 |
204 885 |
|
170 945 |
|
EV, bln rub |
? |
|
195 859 |
293 286 |
241 834 |
241 834 |
231 725 |
|
199 613 |
|
Book value, bln rub |
|
|
-4 219 |
-21 277 |
-14 606 |
-14 696 |
-13 955 |
|
-13 996 |
|
|
EPS, rub |
? |
|
16.1 |
19.6 |
17.7 |
17.7 |
15.5 |
|
16.7 |
|
FCF/share, rub |
|
|
17.2 |
17.8 |
17.6 |
17.6 |
17.9 |
|
21.0 |
|
BV/share, rub |
|
|
-10.7 |
-54.0 |
-37.3 |
-37.5 |
-36.2 |
|
-36.6 |
|
|
EBITDA margin, % |
? |
|
31.6% |
33.1% |
26.2% |
26.6% |
25.2% |
|
24.6% |
|
Net margin, % |
? |
|
19.8% |
19.7% |
15.5% |
15.5% |
14.0% |
|
15.1% |
|
FCF yield, % |
? |
|
3.69% |
2.67% |
3.20% |
3.20% |
3.38% |
|
4.70% |
|
ROE, % |
? |
|
18.5% |
18.9% |
15.8% |
15.8% |
12.8% |
|
13.0% |
|
ROA, % |
? |
|
9.23% |
8.12% |
7.14% |
7.15% |
6.07% |
|
6.34% |
|
|
P/E |
? |
|
28.9 |
34.0 |
31.1 |
31.1 |
34.2 |
|
26.8 |
|
P/FCF |
|
|
27.1 |
37.4 |
31.2 |
31.2 |
29.6 |
|
21.3 |
|
P/S |
? |
|
5.73 |
6.70 |
4.81 |
4.81 |
4.78 |
|
4.04 |
|
P/BV |
? |
|
-43.7 |
-12.4 |
-14.8 |
-14.7 |
-14.7 |
|
-12.2 |
|
EV/EBITDA |
? |
|
19.2 |
22.6 |
20.6 |
20.3 |
21.5 |
|
19.2 |
|
Debt/EBITDA |
|
|
1.12 |
2.34 |
2.21 |
2.17 |
2.49 |
|
2.75 |
|
|
R&D/CAPEX, % |
|
|
80.1% |
55.7% |
65.6% |
65.6% |
90.4% |
|
90.0% |
|
|
CAPEX/Revenue, % |
|
|
4.58% |
6.43% |
4.99% |
4.99% |
3.45% |
|
3.60% |
|
| Thermo Fisher Scientific shareholders |
